Teva Pharmaceutical Industries Ltd.
EU Marketing Authorization Granted for Teva's Aerivio Spiromax® (fluticasone/salmeterol 500/50)
Amsterdam (ots/PRNewswire) - Approval of hybrid high-dose fluticasone/salmeterol maintenance treatment for people living with severe asthma and COPD, delivered via the award-winning Spiromax® inhaler to help patient usability Teva Pharmaceutical Industries Ltd., announced today that it has received EU Marketing Authorization for Aerivio Spiromax® ...